Sanofi-aventis (SNY) signed agreements with Minsheng Pharmaceutical Co., Ltd to form a new consumer healthcare joint venture. Sanofi-aventis is to obtain a majority equity stake in the new venture, subject to certain conditions precedent and to regulatory approvals. The deals were signed in the presence of senior leaders of the Hangzhou municipal government.
The company added that the planned sanofi-aventis-Minsheng joint venture would mainly focus on Vitamins and Mineral Supplements (VMS), where Minsheng has established a strong presence with its flagship multivitamin brand of 21 Super-Vita.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.